Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
Approval Alert | Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
2
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
3
Why Is Burden of Care the Biggest Challenge of Cancer Treatment?
4
The Paradigm of AML Care: What’s New and What’s Changing
5
